The Science Behind Biosimilars: Entering a New Era of Biologic Therapy

Arthritis Rheumatol. 2018 Mar;70(3):334-344. doi: 10.1002/art.40388. Epub 2018 Feb 7.

Authors

S Louis Bridges Jr¹, Douglas W White², Angus B Worthing³, Ellen M Gravallese⁴, James R O'Dell⁵, Kamala Nola⁶, Jonathan Kay⁴, Stanley B Cohen⁷; American College of Rheumatology

Affiliations

¹ University of Alabama at Birmingham.
² Gundersen Health System, La Crosse, Wisconsin.
³ Georgetown University Medical Center and Arthritis & Rheumatism Associates, Washington, DC.
⁴ University of Massachusetts Medical School, Worcester.
⁵ University of Nebraska Medical Center, Omaha.
⁶ Lipscomb University College of Pharmacy and Health Sciences, Nashville, Tennessee.
⁷ Metroplex Clinical Research Center, Dallas, Texas.

PMID: 29411547
DOI: 10.1002/art.40388

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Biological Therapy*
Biosimilar Pharmaceuticals*
Drug Approval*
Drug Industry / legislation & jurisprudence
Humans
United States
United States Food and Drug Administration

Substances

Biosimilar Pharmaceuticals